CLU and pancreatic neoplasm: In another study Tang et al (2012) showed that knockdown of CLU by OGX‐011 sensitized pancreatic cancer cells to gemcitabine by inhibition of gemcitabine‐induced CLU‐mediated pERK1/2 activation.